Compare CAPR & LGIH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAPR | LGIH |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2011 | 2013 |
| Metric | CAPR | LGIH |
|---|---|---|
| Price | $30.24 | $45.09 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 5 |
| Target Price | $44.63 | ★ $75.90 |
| AVG Volume (30 Days) | ★ 968.6K | 400.5K |
| Earning Date | 05-12-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.09 |
| Revenue | N/A | ★ $1,705,504,000.00 |
| Revenue This Year | N/A | $2.32 |
| Revenue Next Year | $3.31 | $17.94 |
| P/E Ratio | ★ N/A | $506.22 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.30 | $33.55 |
| 52 Week High | $40.37 | $69.42 |
| Indicator | CAPR | LGIH |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 50.68 |
| Support Level | $26.06 | $41.82 |
| Resistance Level | $30.06 | $49.51 |
| Average True Range (ATR) | 2.12 | 2.13 |
| MACD | -0.53 | -0.20 |
| Stochastic Oscillator | 19.86 | 19.31 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.